ISTH Academy

Create Account Sign In
August 16, 2022 | ROTEM & TEG as a Resource in the Hemostatic Management in the Inpatient
  • 18:30-19:30 UTC (Universal)
  • 14:30-15:30 EDT (US & Canada)
  • 20:30-21:30 CEST (Central Europe)
  • August 17 | 2:30-3:30 HKT (Asia Pacific)

Understanding and Interpreting Viscoelastic Tests, TEG and ROTEM
by Marina Sol López

  • Introduce participants to the fundamentals of the methodologies, as well as how the graphs are composed
  • Develop the usefulness of different tests available
  • Interpret different graphs in order to determine which hemostatic alteration is present

Use of Viscoelastic Tests in the Critical Care Setting: Utility and Challenges
by David Faraoni, MD, PhD

  • Understand the utility of viscoelastic tests in critical care setting
  • Identify challenges with the implementation of viscoelastic tests in critical care settings
  • Develop strategies to implement viscoelastic tests in the critical care setting

FACULTY

 

Moderator
Oksana Volod, M.D. 

 

Speakers
Marina Sol López
David Faraoni, M.D., Ph.D.

ISTH SSC on the Case - Critical Issues in the Control of Anticoagulation

Questions:
Contact Meriel Parker, MS, Scientific Guidelines and Programs Manager at Meriel_Parker@isth.org

 

The Department of Pediatrics at Johns Hopkins Children’s Hospital (JHCH) has presented a Hematology Case Review Conference to the medical community, its affiliates and collaborators since 2019. In his role as JHCH Hematology Professor and ISTH Pediatric/Neonatal Thrombosis and Hemostasis SSC Subcommittee Chair, Neil Goldenberg proposed for JHCH and ISTH to collaborate and expand the discussions to clinical cases of international interest and relevance. As a result, the ISTH is pleased to announce the launch of its new Clinical Series – SSC On the Case – featuring clinical case presentations by international hematologists and radiologists for discussion with the global clinical community.

Designed to generate treatment consensus, cultivate specialist’s recommendations, and educate the broader medical community on methodology and disease mechanisms, this new clinical case series expands the common hospital case dialogue beyond its conference room walls, to the boundless community of international hematology specialists.

FACULTY

 

Moderator
Adam Cuker, University of Pennsylvania
Pennsylvania, USA

 

Co-Moderator
Thita Joy Chiasakul, King Chulalongkorn Memorial Hospital
Chulalongkorn University
Bangkok, Thailand

 

Case Presenter #1
Allyson Pishko, University of Pennsylvania
Pennsylvania, USA

 

Case Presenter #2
Tarinee Rungjirajittranon, Siriraj Hospital
Mahidol University
Bangkok, Thailand

Learning Objectives | Upon completion of the activity, participants should be able to:
  • Describe how novel agents for patients with hemophilia, including those targeting antithrombin, FVIIIa, and tissue factor pathway inhibitor (TFPI), are being developed to enhance and rebalance the hemostatic system
  • Summarize current clinical studies of these novel therapies for hemophilia
  • Outline potential concerns regarding these novel therapies

This interactive learning module is a self-directed educational activity, led by experts Dr. Michelle Sholzberg and Dr. Angela Weyand. Topics include new and emerging treatments, novel agents that are being developed, current clinical studies, and potential concerns of novel therapies.

 

ACCREDITATION STATEMENT
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Physician Assistant
PAs may claim a maximum of 1 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

Furthermore, TFF and ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
 

Faculty:

Michelle Sholzberg, M.D.

Clinical and Laboratory Hematologist
Unity Health Toronto
Toronto, Canada

 

Angela Weyand, M.D.

Pediatric Hematologist-Oncologist
C.S. Mott Children’s Hospital
Ann Arbor, MI

 

 

Cerebral and Portal Vein Thrombosis

Cerebral Venous Thrombosis: An Update
by Diana Aguiar de Sousa, M.D., Ph.D.

  • Summarize recent advances on the diagnosis and management of patients with CVT
  • Provide an overview of new insights into the pathophysiology of brain damage in CVT
  • Briefly summarize what is currently known about CVT, related to vaccine induced thrombotic thrombocytopenia 

Portal Vein Thrombosis
by Nicoletta Riva, M.D., Ph.D. 

  • Describe the main risk factors for portal vein thrombosis
  • Evaluate the role of the different imaging techniques for portal vein thrombosis
  • Apply the general principles of anticoagulant therapy to patients with portal vein thrombosis

FACULTY

 

Moderator
Leonardo Brandão, M.D.

 

Speakers
Diana Aguiar de Sousa, M.D., Ph.D.
Nicoletta Riva, M.D., Ph.D.

ISTH SSC on the Case: Women's Health Issues on Thrombosis and Hemostasis

Questions:
Contact Meriel Parker, MS, Scientific Guidelines and Programs Manager at Meriel_Parker@isth.org

 

The Department of Pediatrics at Johns Hopkins Children’s Hospital (JHCH) has presented a Hematology Case Review Conference to the medical community, its affiliates and collaborators since 2019. In his role as JHCH Hematology Professor and ISTH Pediatric/Neonatal Thrombosis and Hemostasis SSC Subcommittee Chair, Neil Goldenberg proposed for JHCH and ISTH to collaborate and expand the discussions to clinical cases of international interest and relevance. As a result, the ISTH is pleased to announce the launch of its new Clinical Series – SSC On the Case – featuring clinical case presentations by international hematologists and radiologists for discussion with the global clinical community.

Designed to generate treatment consensus, cultivate specialist’s recommendations, and educate the broader medical community on methodology and disease mechanisms, this new clinical case series expands the common hospital case dialogue beyond its conference room walls, to the boundless community of international hematology specialists.

FACULTY

 

Chairs
Robert Sidonio
Rezan Abdul-Kadir
Offer Erez

 

Speakers
Ozlem Turan
Sharon Davidesko

Learning Objectives | Upon completion of the activity, participants should be able to:
  • Distinguish HIT from other thrombocytopenias based on clinical and laboratory components
  • Summarize the elements of the 4Ts scoring system for diagnosis of HIT and the assays used to confirm the diagnosis
  • Interpret the predictive power of low, intermediate and high 4T scores in diagnosing HIT
  • Differentiate immunoassays and rapid assays from functional assays, and describe their significance in complementing a clinical evaluation for HIT
Learning Objectives- Upon completion of the activity, participants should be able to:
  • Discuss with clinical colleagues the appropriate use of specific DOAC reversal agents
  • Explain efficacy and safety of the pharmacotherapeutic options for DOAC reversal
  • Advise on appropriate institutional approaches to DOAC reversal agents

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  6. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards

CLICK HERE TO VIEW TECHNICAL REQUIREMENTS


ACCREDITED PROVIDER
This activity is jointly provided by The France Foundation and International Society on Thrombosis and Haemostasis.

TARGET AUDIENCE
This activity is intended for members of the hematology team, including hematologists, nurse practitioners, and PAs specializing in hematology.

STATEMENT OF NEED
This program is designed to provide education that prepares the hematology team to provide clinical and institutional consultations on the pharmacologic options to manage DOAC-related bleeding, their specific indications, and safety and efficacy considerations.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and International Society on Thrombosis and Haemostasis. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physician

The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

 

 

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and International Society on Thrombosis and Haemostasis (ISTH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, and other members at International Society on Thrombosis and Haemostasis who control content have no relevant financial relationships to disclose.

Faculty Disclosures
The following faculty report that they have relevant financial relationships to disclose:

  • Deborah Siegal, MD, MSc, FRCPC, has received speaker fees from Aspen Pharma, BMS‐Pfizer, Leo Pharma, Novartis, Portola, and Servier
  • Geoffrey Barnes, MD, MSc, is a consultant for Pfizer/Bristol Myers Squibb, Janssen, and AMAG Pharmaceuticals

DISCLOSURE OF UNLABELED USE
TFF and ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc.

DISCLAIMER
The France Foundation and International Society on Thrombosis and Haemostasis present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, International Society on Thrombosis and Haemostasis, and the commercial supporter assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2021 The France Foundation and The American Society of Hematology. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.


PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy-policy.


CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Faculty

Deborah Siegal, MD, MSc,
Associate Professor, Department of Medicine
University of Ottawa
Associate Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada

 

Geoff Barnes, MD, MSc
Assistant Professor of Internal Medicine
Vascular and Cardiovascular Medicine
Director, Vascular Medicine Fellowship
Frankel Cardiovascular Center
University of Michigan
Ann Arbor, Michigan

We found no results for your search. Please change or remove at least one filter to broaden your search.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies